Solventum Corporation (SOLV) Stock Forecast & Price Target

Solventum is well positioned because it continues to beat expectations on revenue, EPS, and margins, with 3Q revenue of $1,949M, adjusted operating margin of 19.9%, and EPS of $1.45, while management raised guidance for the third time this year. Its portfolio is becoming cleaner and more focused after the purification and filtration sale and the planned HIS separation, leaving a core medtech consumables franchise where MedSurg is about 64% of revenue and still has significant penetration opportunities in infection prevention, wound care, and NPWT. The outlook is further supported by normalized Dental growth, expected margin expansion toward 23% to 25%, and free cash flow inflecting materially as separation costs roll off and the 3M supply agreement removes a future gross-margin headwind.

Solventum is vulnerable to slower growth in its key businesses, especially as medsurg, which now represents about 64% of consolidated revenue, and the two 18% segments, dental solutions and health information systems, must offset weakness in a more concentrated portfolio after the purification and filtration sale. Its outlook is further pressured by slower improvement in operating margins, which limits earnings leverage and makes the company more dependent on steady execution across advanced wound care, infection prevention, restorative composites, orthodontia, and revenue cycle management. Higher interest rates could lift interest expense, while intensifying competition and any negative updates on the separation of SOLV's HIS segment could weigh on sentiment and impair share performance.